Metallopharmaceutical complexes based on vanadium as potential anti-hyperglycemic agents | ||||
Egyptian Journal of Chemistry | ||||
Article 3, Volume 63, Issue 2, February 2020, Page 389-404 PDF (1.43 MB) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/ejchem.2019.13511.1837 | ||||
![]() | ||||
Authors | ||||
Ramy Mohamed Abd Elaziz ![]() | ||||
1Biochemistry,faculty of pharmacy,The British University in Egypt | ||||
2Chemistry,faculty of science,Menoufia University,Egypt | ||||
3Pharmacology,faculty of pharmacy, The British university in Egypt | ||||
4Pathology,faculty of medicine,Menoufia University,Egypt | ||||
Abstract | ||||
Interaction between vanadium pentoxide and bioactive Schiff–bases led to the formation of vanadium (III/IV) complexes. Ten complexes have been characterized using mass, IR, UV-VIS and ESR spectra, magnetic moments and conductance measurements as well as elemental and thermal analyses. Magnetic moments and ESR measurements confirmed vanadium complexes have (III/IV) oxidation state. Conductivity measurements indicate that complexes are not electrolytes. A representative set of vanadium (III/IV) complexes in varying coordination environments have been tested as anti-hyperglycemic agents against type 2 diabetes mellitus in concentration doses (30 and 100 µM/Kg) using female albino rats. The pharmacological data showed that, complexes 1 and 8 produced significant decrease in blood glucose level. Furthermore, these two complexes showed an improvement in liver and kidney function after daily administration for two weeks. | ||||
Keywords | ||||
vanadium complexes; ESR; spectra; magnetism; pathological; Type 2 Diabetes; anti-hyperglycemic | ||||
Statistics Article View: 699 PDF Download: 495 |
||||